Roivant Sciences News - October 2026
🟢 Roivant Sciences is trading 5% up today after brepocitinib met both Phase 3 primary endpoints
Roivant Sciences is trading at $36.68, up 5.04%, after brepocitinib met primary endpoints in both Phase 3 CLARITY trials for non-infectious uveitis. - At Week...
🟢 Roivant Sciences is trading 10.5% up in pre-market after brepocitinib met primary endpoints in both trials
Roivant Sciences is trading at $38.60, up 10.54%, after positive Phase 3 results for brepocitinib in non-infectious uveitis. - CLARITY-1 and CLARITY-2 met...
🟢 Roivant Sciences is trading 23.22% up in after-hours trading; catalyst remains unclear
Roivant Sciences is trading at $41.32, up 23.22%, with the after-hours catalyst unclear. - No verified October 16 company-specific announcement surfaced to...